HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance

Kideok Jin, Sunju Park, Wei Wen Teo, Preethi Korangath, Sean Soonweng Cho, Takahiro Yoshida, Balázs Győrffy, Chirayu Pankaj Goswami, Harikrishna Nakshatri, Leigh Ann Cruz, Weiqiang Zhou, Hongkai Ji, Ying Su, Muhammad Ekram, Zhengsheng Wu, Tao Zhu, Kornelia Polyak, Saraswati Sukumar

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor-a (ERa) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 chromatin immunoprecipitation analysis followed by validation showed that HOXB7 physically interacts with ERa, and that the HOXB7–ERa complex enhances transcription of many ERa target genes, including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR–HER2 signaling, inhibits transcription of miR-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER target genes, and HER2. Repressing MYC using small-molecule inhibitors reverses these events and causes regression of breast cancer xenografts. The MYC–HOXB7–HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer. SIGNIFICANCE: HOXB7 acts as an ERa cofactor regulating a myriad of ER target genes, including HER2, in tamoxifen-resistant breast cancer. HOXB7 expression is controlled by MYC via transcriptional regulation of the HOXB7 repressor miR-196a; consequently, antagonists of MYC cause reversal of selective ER modulator resistance both in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)944-959
Number of pages16
JournalCancer Discovery
Volume5
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

erbB-2 Genes
Estrogen Receptors
Breast Neoplasms
Tamoxifen
Genes
Chromatin Immunoprecipitation
Heterografts
Phosphorylation
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. / Jin, Kideok; Park, Sunju; Teo, Wei Wen; Korangath, Preethi; Cho, Sean Soonweng; Yoshida, Takahiro; Győrffy, Balázs; Goswami, Chirayu Pankaj; Nakshatri, Harikrishna; Cruz, Leigh Ann; Zhou, Weiqiang; Ji, Hongkai; Su, Ying; Ekram, Muhammad; Wu, Zhengsheng; Zhu, Tao; Polyak, Kornelia; Sukumar, Saraswati.

In: Cancer Discovery, Vol. 5, No. 9, 01.09.2015, p. 944-959.

Research output: Contribution to journalArticle

Jin, K, Park, S, Teo, WW, Korangath, P, Cho, SS, Yoshida, T, Győrffy, B, Goswami, CP, Nakshatri, H, Cruz, LA, Zhou, W, Ji, H, Su, Y, Ekram, M, Wu, Z, Zhu, T, Polyak, K & Sukumar, S 2015, 'HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance', Cancer Discovery, vol. 5, no. 9, pp. 944-959. https://doi.org/10.1158/2159-8290.CD-15-0090
Jin, Kideok ; Park, Sunju ; Teo, Wei Wen ; Korangath, Preethi ; Cho, Sean Soonweng ; Yoshida, Takahiro ; Győrffy, Balázs ; Goswami, Chirayu Pankaj ; Nakshatri, Harikrishna ; Cruz, Leigh Ann ; Zhou, Weiqiang ; Ji, Hongkai ; Su, Ying ; Ekram, Muhammad ; Wu, Zhengsheng ; Zhu, Tao ; Polyak, Kornelia ; Sukumar, Saraswati. / HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. In: Cancer Discovery. 2015 ; Vol. 5, No. 9. pp. 944-959.
@article{b0dfa8675295431097488e6b38bb44f0,
title = "HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance",
abstract = "Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor-a (ERa) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 chromatin immunoprecipitation analysis followed by validation showed that HOXB7 physically interacts with ERa, and that the HOXB7–ERa complex enhances transcription of many ERa target genes, including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR–HER2 signaling, inhibits transcription of miR-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER target genes, and HER2. Repressing MYC using small-molecule inhibitors reverses these events and causes regression of breast cancer xenografts. The MYC–HOXB7–HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer. SIGNIFICANCE: HOXB7 acts as an ERa cofactor regulating a myriad of ER target genes, including HER2, in tamoxifen-resistant breast cancer. HOXB7 expression is controlled by MYC via transcriptional regulation of the HOXB7 repressor miR-196a; consequently, antagonists of MYC cause reversal of selective ER modulator resistance both in vitro and in vivo.",
author = "Kideok Jin and Sunju Park and Teo, {Wei Wen} and Preethi Korangath and Cho, {Sean Soonweng} and Takahiro Yoshida and Bal{\'a}zs Győrffy and Goswami, {Chirayu Pankaj} and Harikrishna Nakshatri and Cruz, {Leigh Ann} and Weiqiang Zhou and Hongkai Ji and Ying Su and Muhammad Ekram and Zhengsheng Wu and Tao Zhu and Kornelia Polyak and Saraswati Sukumar",
year = "2015",
month = "9",
day = "1",
doi = "10.1158/2159-8290.CD-15-0090",
language = "English (US)",
volume = "5",
pages = "944--959",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance

AU - Jin, Kideok

AU - Park, Sunju

AU - Teo, Wei Wen

AU - Korangath, Preethi

AU - Cho, Sean Soonweng

AU - Yoshida, Takahiro

AU - Győrffy, Balázs

AU - Goswami, Chirayu Pankaj

AU - Nakshatri, Harikrishna

AU - Cruz, Leigh Ann

AU - Zhou, Weiqiang

AU - Ji, Hongkai

AU - Su, Ying

AU - Ekram, Muhammad

AU - Wu, Zhengsheng

AU - Zhu, Tao

AU - Polyak, Kornelia

AU - Sukumar, Saraswati

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor-a (ERa) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 chromatin immunoprecipitation analysis followed by validation showed that HOXB7 physically interacts with ERa, and that the HOXB7–ERa complex enhances transcription of many ERa target genes, including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR–HER2 signaling, inhibits transcription of miR-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER target genes, and HER2. Repressing MYC using small-molecule inhibitors reverses these events and causes regression of breast cancer xenografts. The MYC–HOXB7–HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer. SIGNIFICANCE: HOXB7 acts as an ERa cofactor regulating a myriad of ER target genes, including HER2, in tamoxifen-resistant breast cancer. HOXB7 expression is controlled by MYC via transcriptional regulation of the HOXB7 repressor miR-196a; consequently, antagonists of MYC cause reversal of selective ER modulator resistance both in vitro and in vivo.

AB - Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor-a (ERa) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 chromatin immunoprecipitation analysis followed by validation showed that HOXB7 physically interacts with ERa, and that the HOXB7–ERa complex enhances transcription of many ERa target genes, including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR–HER2 signaling, inhibits transcription of miR-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER target genes, and HER2. Repressing MYC using small-molecule inhibitors reverses these events and causes regression of breast cancer xenografts. The MYC–HOXB7–HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer. SIGNIFICANCE: HOXB7 acts as an ERa cofactor regulating a myriad of ER target genes, including HER2, in tamoxifen-resistant breast cancer. HOXB7 expression is controlled by MYC via transcriptional regulation of the HOXB7 repressor miR-196a; consequently, antagonists of MYC cause reversal of selective ER modulator resistance both in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84941771775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941771775&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-15-0090

DO - 10.1158/2159-8290.CD-15-0090

M3 - Article

C2 - 26180042

AN - SCOPUS:84941771775

VL - 5

SP - 944

EP - 959

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 9

ER -